Please assess the completion status of the following clinical trial:

Trial Title: Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females of all races between 18 to 80 years of age.~* Diagnosed with primary autonomic failure and supine hypertension. Supine hypertension will be defined as systolic blood pressure \> 150 mmHg and/or diastolic blood pressure \> 90 mmHg while lying down.~* Able and willing to provide informed consent.~Exclusion Criteria:~* Pregnancy or breast feeding.~* Hemoglobin \< 10.5 or hematocrit \< 32.~* High-risk patients (e.g. heart failure, symptomatic coronary artery disease, liver impairment, renal failure, history of stroke or myocardial infarction).~* Inability to give or withdraw informed consent.~* Other factors which in the investigator's opinion would prevent the patient from completing the protocol (e.g. clinically significant abnormalities on clinical, mental examination, or laboratory testing or inability to comply with the protocol).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Angiotensin-(1-7) (Type: EXPERIMENTAL): Patients will receive an intravenous infusion of five ascending doses of Angiotensin-(1-7). The doses are: 1, 2, 4, 8 and 16 ng/kg/min. Each dose will be maintained for 10 minutes, for a total of 50 minutes.
- Saline (Type: PLACEBO_COMPARATOR): Patients will receive an intravenous infusion of saline that is matched in volume to the Angiotensin-(1-7) study day. The saline infusion will be maintained for 50 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).